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Pseudomonas aeruginosa is amajor opportunistic human pathogen, responsible for nosocomial infections and infections in patients
with impaired immune systems. Little data exist about the faecal colonisation by P. aeruginosa isolates in healthy humans. The
occurrence, antimicrobial resistance phenotype, virulence genotype, and genetic lineages of P. aeruginosa from faecal samples of
children from two different Spanish regions were characterised. Seventy-two P. aeruginosa were isolated from 1,443 faecal samples.
Low antimicrobial resistance levels were detected: ceftazidime (8%), cefepime (7%), aztreonam (7%), gentamicin (3%), ciprofloxacin
(1%), and imipenem (1%); susceptibility to meropenem, amikacin, tobramycin, levofloxacin, and colistin. Four multidrug-resistant
strainswere found. Important differenceswere detected between both geographical regions. Forty-one sequence typeswere detected
among the 48 tested strains. Virulence and quorum sensing genes were analysed and 13 virulotypes were detected, being 26
exoU-positive strains. Alteration in protein OprD showed eight different patterns. The unique imipenem-resistant strain showed
a premature stop codon in OprD. Intestinal colonisation by P. aeruginosa, mainly by international clones (as ST244, ST253, and
ST274), is an important factor for the systemic infections development and the environmental dissemination. Periodic active
surveillance is useful to identify these community human reservoirs and to control the evolution of antibiotic resistance and
virulence activity.
1. Introduction
Pseudomonas aeruginosa is a ubiquitous Gram-negative bac-
teria present in many diverse environmental settings, includ-
ing different living sources, such as animals and humans.
The ability of P. aeruginosa to survive on minimal nutritional
requirements and to tolerate a variety of physical conditions
has allowed this organism to persist in both community and
hospital settings [1]. This species is a major opportunistic
human pathogen, responsible for worldwide nosocomial
infections with increasing medical and veterinary impor-
tance [1] and causing infections mostly in patients with
impaired immune systems [2]. P. aeruginosa shows high
intrinsic resistance to antibiotics and has an extraordinary
capacity to acquire new resistance mechanisms [3–5]. The
increasing prevalence ofmultidrug-resistant (MDR) P. aerug-
inosa isolates is a global health problem, because of the
limitation in clinical treatment options [5, 6].
This microorganism is seldom a member of the normal
microbiota in humans. Colonisation rates in the range of
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2.6 to 24% have been reported in human faecal samples
[1, 3, 7]. Nevertheless, other studies show a high prevalence
of P. aeruginosa in small intestinal and faecal samples from
irritable bowel syndrome patients [7]. Relatively little data
exist so far about the faecal colonisation by P. aeruginosa iso-
lates in healthy humans, as well as about their antimicrobial
resistance and virulence characteristics [1, 3, 7, 8]. Children
tend to be exposed to more disease-causing bacteria through
diary activities such as childcare and mouthing behaviours;
they are more vulnerable to bacterial illness than adults, and
they develop many nonfatal bacterial infections that require
antimicrobial treatments, whereas no descriptions exist about
the faecal carriage and characterisation of P. aeruginosa
isolates from children. For that reason, the aim of this study
was to determine the occurrence, the antimicrobial resistance
phenotypes, the virulence genotypes, and the genetic lineages
of P. aeruginosa in faecal samples of children from two
Spanish regions (La Rioja and Arago´n).
2. Material and Methods
2.1. Bacterial Strains. A total of 966 faecal samples of children
were recovered in the Hospital Cl´ınico Universitario Lozano
Blesa (HLB) (Zaragoza, Arago´n, Spain) from June to October
2013 and 477 samples in the Hospital San Pedro (HSP)
(Logron˜o, La Rioja, Spain) from June toAugust 2014. La Rioja
and Arago´n are close regions but have different epidemiology
settings. All children under 15 years old, who attended the
hospital primary cares with gastroenteritis, food allergies, or
disorders and with a microbiological study of their stools,
were included in the study. The recruitment was the same in
both hospitals. Samples were recovered from unique patients
without repeated sampling from same patients. Samples were
streaked onto cetrimide agar plates. After incubation at
37∘C during 24h, one colony per sample with P. aeruginosa
morphology was selected. Identification of the isolates was
performed by classical biochemicalmethods andMicroScan
WalkAway (Siemens) microdilution system.
2.2. Antimicrobial Susceptibility Testing. In vitro antimicro-
bial susceptibility testing was performed byMicroScanWalk-
Away (Siemens) microdilution system following the Clinical
and Laboratory Standards Institute (CLSI) guidelines [9].
Thirteen antimicrobial agents were tested, including (range
of testedMinimal Inhibitory Concentration in 𝜇g/mL, MIC):
ticarcillin (8-32), piperacillin-tazobactam (8/4-64/4), aztre-
onam (1-16), cefepime (1-16), ceftazidime (1-32), meropenem
(1-8), imipenem (1-8), tobramycin (2-8), gentamicin (1-8),
amikacin (8-32), levofloxacin (1-4), ciprofloxacin (0.5-2), and
colistin (2-4). Extended-spectrum-beta-lactamase (ESBL),
metallo-beta-lactamase (MBL), and class A carbapenemase
phenotypes were determined by double-disc synergy tests
[10–12].
2.3. Molecular Typing. The clonal relationship among
the recovered isolates was determined by pulsed-field gel
electrophoresis (PFGE) with SpeI restriction enzyme to di-
gest genomic DNA [3].
Multilocus sequence typing (MLST) for P. aeruginosawas
performed by PCR and sequencing of seven housekeeping
genes (acsA, aroE, guaA, mutL, nuoD, ppsA, and trpE) [13]
(see Table S1 Supplementary Material). Allelic profiles and
sequence types (STs) were compared with the PubMLST
database (http://pubmlst.org/paeruginosa/). New STs were
submitted to the PubMLST website.
2.4. Virulence Marker Genes. The following virulence and
quorum sensing geneswere analysed by PCR [14]: exoU, exoS,
exoY, exoT, lasA, lasB, exoA, aprA, rhlAB, rhlI, rhlR, lasI, and
lasR (see Table S1 Supplementary Material).
2.5. Detection and Characterisation of Integrons. The pres-
ence of genes encoding type 1, 2, and 3 integrases, and 3󸀠-
conserved segment of class 1 integrons (qacEΔ1+sul1) was
studied by PCR. The characterisation of class 1 integron
variable regions was carried out by PCR mapping and
sequencing [15] (see Table S1 Supplementary Material).
2.6. Characterisation of OprD Porin. The amino acid changes
of the porin protein OprD were analysed by PCR and
sequencing in all P. aeruginosa strains [16, 17] (see Table S1
Supplementary Material). The mutations were determined
by comparison with the sequence of the control strain P.
aeruginosa PAO1 (GenBank accession number AE004091).
The outer membrane proteins of selected strains were
obtained and visualized by SDS-PAGE (Sodium Dodecyl
Sulphate-PolyAcrylamide Gel Electrophoresis) in a Bio-
Rad apparatus (Mini-Protean II) and were stained with
Coomassie Brilliant Blue as previously described [18]. The P.
aeruginosa PAO1 and PAO1 lacking-OprD were included as
control strains.
3. Results
3.1. P. aeruginosa Isolates and Antimicrobial Susceptibility.
A total of 72 P. aeruginosa were isolated from 1,443 faecal
samples of children (5%): 42 isolates were obtained in
HLB (4.3%) and the 30 remaining ones in HSP (6.3%).
Campylobacter, Salmonella, Giardia, adenovirus, or rotavirus
were the microorganisms involved in the diagnosis of 12
out of the 72 P. aeruginosa-positive children. Only 10 of
the 72 children showed any underlying disease (number
of children): atopic dermatitis (2), weight delay (2), lactose
intolerance (2), Williams syndrome (1), anorexia (1), cystic
fibrosis (1), or psychomotor disturbance/delay (1). No relation
was detected between the clinical background of the children
and the P. aeruginosa isolates (see Table S2 Supplementary
Material).
All isolates fromHSPwere susceptible to all antimicrobial
agents tested, with the exception of one isolate that was
ceftazidime resistant. On the other hand, the 42 P. aeruginosa
isolates from HLB showed the following resistance per-
centages to cefepime, 11.9%; piperacillin-tazobactam, 11.9%;
ticarcillin, 11.9%; aztreonam, 11.9%; ceftazidime, 11.9%; gen-
tamicin, 4.7%; imipenem, 2.4%; ciprofloxacin, 2.4% and were
susceptible to meropenem, amikacin, tobramycin, levoflox-
acin, and colistin. Only 4 multidrug-resistant isolates were
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Table 1: Virulence patterns detected among the 72 P. aeruginosa isolated from faecal samples of children.
No. strains Amplification of genes Virulence pattern
exoU exoS exoY exoT exoA lasA lasB aprA rhlAB rhlI rhlR lasI lasR
39 - + + + + + + + + + + + + I
1 - + + + + + + + + + + + +a II
1 - + - + + + + + + + + + + III
1 - + + - + + + + + + + + + IV
1 - + + + + + + + + + - + + V
2 - + + + + + + + + + + - - VI
14 + - + + + + + + + + + + + VII
1 + - + + + + + + + + + + +b VIII
6 + - - + + + + + + + + + + IX
1 + - - + + + + + + + + + +c X
2 + - - + + + + + + + - + + XI
2 + + + + + + + + + + + + + XII
1 - - - - - + + + + - - + + XIII
a lasR gene truncated by ISPpu17 element
b lasR gene truncated by IS1394 element
c lasR gene truncated by IS1246 element
found (Pc31, Pc33, Pc40, and Pc43). None of the 72 isolates
showed class A carbapenemase, MBL, or ESBL phenotypes.
Only two out of the 72 P. aeruginosa-harbouring chil-
dren had received antibiotic treatment in the three months
previous to sampling: i.e., one cystic fibrosis child (indi-
vidual 44) who took amoxicillin-clavulanic acid due to
methicillin-susceptible S. aureus presence and another child
(individual 60) who suffered a urine infection and took
meropenem, whereas the P. aeruginosa isolated from both
patients were piperacillin-tazobactam-resistant and suscep-
tible, respectively.
3.2. Clonal Relationship and Molecular Typing. Sixty-eight
different PFGE patterns were detected among the 72 P.
aeruginosa: 39 different PFGE patterns among the 42 isolates
from HLB, and 29 among the 30 P. aeruginosa isolates from
HSP. No relationship was found among strains fromHLB and
those from HSP.
The sequence types (ST) were determined among 48 P.
aeruginosa strains using MLST method. Forty-one different
sequence types were observed, five of them (ST2221, ST2222,
ST2223, ST2241, and ST2242) being firstly described in this
study and were annotated in the MLST database. Six ST were
repeated more than once: ST27 (n=2 strains), ST244 (n=3),
ST253 (n=2), ST313 (n=2), ST390 (n=2), and ST667 (n=2) (see
Table S2 Supplementary Material).
3.3. Detection of Virulence Markers. The distribution of thir-
teen genes involved virulence, type III secretion system
(T3SS), and quorum sensing system was investigated among
the 72 P. aeruginosa strains, and thirteen different profiles
were obtained (Table 1).
The T3SS exoU gene was detected in 26 P. aeruginosa
strains and the exoS in 47 strains. Both genes were amplified
in two strains that were confirmed by three independent
experiments and sequencing of the amplicons. On the other
hand, neither exoU nor exoS genes were amplified in one
strain that also lacked exoY, exoT, exoA, rhlI, and rhlR genes.
At least one of the genes involved in quorum sensing (lasI,
lasR, rhlI, or rhlR) was not amplified in six strains. However,
lasA, lasB, aprA, and rhlAB genes were amplified in all strains
(Table 1). The lasR amplicon sized higher than 2,000 bp in
three strains (Pc5, Pc10, and Ps519). After sequencing, the
insertion sequences IS1246, ISPpu17 and IS1394, respectively,
were detected surrounding lasR gene. IS1246 was detected
upstream of lasR gene in Pc5 strain. ISPpu17 was observed
truncating lasR gene at position 660 in Pc10 strain, and IS1394
at position 639 in Ps519 strain; therefore those sequences
were submitted inGenBank databasewith accession numbers
MH050328 and MG815635, respectively.
3.4. Detection and Characterisation of Integrons. No class 1,
2, or 3 integrases were detected among the 72 P. aeruginosa
strains.
3.5. Characterisation of Porin OprD. The oprD gene was
amplified in all P. aeruginosa strains, and their OprD amino
acid sequences (443 amino acids) were compared with the
OprD sequence of reference P. aeruginosa PAO1. Table 2
shows the polymorphism detected in OprD sequences. Eight
OprD profiles were distinguished among the 72 P. aeruginosa
strains, all but one strain being imipenem-susceptible ones.
Only four strains had the same pattern as P. aeruginosa
PAO1, and the pattern B was the most frequently detected (31
strains). Among the amino acid changes detected in OprD
loop 1 (44 to 61 amino acid (aa)), the most frequent ones were
D43N, S57E, and S59R (31 strains, 43%). Alterations in loop
2 (93 to 127 aa) were observed in 51% of the P. aeruginosa
strains, T103S and K115T being themost frequent in 21 strains
and V127L in 16 strains.The E185Q, P186G, andV189T amino
acid changes were the most common described in loop 3
(153 to 192 aa) followed by F170L. On the other hand, E230K
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Table 2: Polymorphisms detected in porin OprD of the 72 P. aeruginosa isolates from faecal samples of children.
Strains (n∘ total)a OprD Size OprDPattern Amino acid Changes
Ps514, Pc6, Pc10, Pc15 (4) 443 A WILD
Ps488, Ps492, Ps493, Ps494, Ps495, Ps496, Ps497, Ps501,
Ps502, Ps507, Ps510, Ps515, Ps516, Ps518, Ps520, Ps521,
Pc3, Pc8, Pc11, Pc12, Pc13, Pc17, Pc19, Pc22, Pc24, Pc26,
Pc27, Pc28, Pc35, Pc39, Pc43 (31)
441 B
D43N; S57E; S59R; E202Q; I210A; E230K; S240T;
N262T; A267S; A281G; K296Q; Q301E; R310G; V359L;
Loop L7-short
Ps487, Ps498, Ps500, Ps517, Ps519, Ps522, Pc4, Pc5, Pc7,
Pc14, Pc18, Pc20, Pc29, Pc30, Pc40, Pc42 (16) 443 C
T103S; K115T; F170L; E185Q; P186G; V189T; R310E;
A315G; G425A
Ps489, Ps491, Ps499, Ps505, Ps512, Pc2, Pc23, Pc33, Pc37,
Pc38, Pc41 (11) 441 D
S57E; S59R; V127L; E185Q; P186G; V189T; E202Q;
I210A; E230K; S240T; N262T; T276A; A281G; K296Q;
Q301E; R310E; A315G; L347M; Loop L7-short; S403A;
Q424E
Pc16, Pc31, Pc32, Pc36 (4) 441 E
V127L; E185Q; P186G; V189T; E202Q; I210A; E230K;
S240T; N262T; T276A; A281G; K296Q; Q301E; R310E;
G312R; A315G; L347M; Loop L7-short; S403A; Q424E
Ps486, Pc9, Pc21, Pc25 (4) 443 F T103S; K115T; F170L
Ps506 (1) 443 G D43N; T103S; K115T; F170L
Pc1 (1) 277 H
G60R; T105A; V127L; E185Q; P186G; V189T; E202Q;
I210A; E230K; S240T; S248E; N262T; A267S;
W277STOP
change in the loop 4 (221 to 233 aa) was detected in 47 of
the strains. The N262T and A267S amino acid changes in
loop L5 (260 to 274 aa) and R310E and A315G in loop 6
(304 to 317 aa) were identified. Thirty-one strains showed
the G425A or Q424E substitutions in loop 8 (418 to 431
aa). In the region from 372 to 383 aa of the loop 7, the
deletion of two amino acids (loop L7-short), which encoded a
protein OprD of 441 amino acids, was identified in 46 strains
(64%).
Only the imipenem-resistant strain (Pc1) showed a pre-
mature stop codon, due to a point mutation which modifies
the expected OprD protein (pattern H in Table 2).
A total of 6 P. aeruginosa strains (Ps514, Ps518, Ps487,
Ps499, Ps486, and Ps506)with different proteinOprDprofiles
were selected to study their outermembrane proteins by SDS-
PAGE. OprD band was detected in all tested strains.
4. Discussion
This study intended to gain new insights into the P. aerugi-
nosa in non-clinical environments, analysing the occurrence,
and characteristics of P. aeruginosa from faecal samples of
children. In fact, the occurrence of P. aeruginosa isolates
in this study (5%) (HSP 6.3% and HLB 4.3%) was in the
range detected in other studies (2.6-24%) [3, 7].The presence
of P. aeruginosa in stool constitutes a digestive reservoir of
the bacteria that may be of importance in P. aeruginosa
pathophysiology. In our case, there is not any association
between diagnosis or clinical symptoms of the children and
the P. aeruginosa detection.
Additionally, low antimicrobial resistance levels were
detected for ceftazidime (8%), cefepime (7%), aztreonam
(7%), gentamicin (3%), ciprofloxacin (1%), or imipenem (1%)
among the isolates tested. Only four multidrug-resistant
strains were found. High susceptibility rates were detected
among the P. aeruginosa isolates from Logron˜o (La Rioja).
In a previous work performed in the same region by our
group, all eight P. aeruginosa isolated from healthy humans
were susceptible to all tested antibiotics [3]. All these results
contrast with the frequent multidrug-resistant P. aeruginosa
detected in studies carried out with clinical strains [5, 6].
Additionally, in our study, only one imipenem-resistant strain
was found and this resistance was associated with the loss of
porin OprD by a premature stop codon (277 amino acids).
Porin OprD serves as the imipenem entryway, and the pres-
ence of premature stop codons or certain insertions/deletions
in the oprD sequence involves the OprD loss and confers
carbapenem resistance in P. aeruginosa [1, 6, 16]. On the other
hand, a wide variety of amino acid changes were detected in
OprD of the remaining 71 P. aeruginosa strains of our study,
even if they were susceptible to imipenem or meropenem.
Thirty-one of our strains (43%) contained the same changes
in protein OprD (D43N, S57E, S59R, E202Q, I210A, E230K,
S240T, N262T, A267S, A281G, K296Q,Q301E, R310G, V359L,
and loop L7-short). Some of these amino acid changes
had been shown by other authors, in both carbapenem-
susceptible and -resistant strains [19–22]. It is known that
L2 and L3 loops are involved in binding to imipenem [23–
25]. However, most of our strains showed substitutions in
both loops andwere carbapenem-susceptible, as other studies
previously described [22]. The deletion of two amino acids,
named loop L7-short, identified in 48 of these strains has
been previously described in both MBL-producing and non-
MBL-producing isolates [6]. Summarising, there is a high
polymorphism in the oprD gene of our P. aeruginosa strains,
but neither the loop L7-short nor amino acid changes, with
the exception of the premature stop codon, were associated
with carbapenem resistance.
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Regarding molecular typing, a wide variety of sequence
types has been found in this study (41 different ST among
the 48 P. aeruginosa strains tested), in contrast to other
studies with clinical P. aeruginosa isolates, in which mainly
appeared the “high-risk clones” ST111, ST175, and ST235.
Some works showed that a high genetic diversity is associated
with low rates of antimicrobial resistance, as our work has
also demonstrated [8, 26]. So, the spread of these different STs
among the community is independent from the antimicrobial
resistance, but other features could be involved such as
host adaptation (virulence, biofilm activity. . .). Among the
diversities of STs found in this work, intercontinental clones
were encountered: ST27, ST244, ST274, ST277, ST395, ST446,
and ST560 [27]. ST244 that was detected in three strains
from both regions is a global P. aeruginosa clone identified in
several countries, among different origins (clinical, animal,
and environmental), and associated with different antimi-
crobial resistance phenotypes (MDR or susceptible strains)
and genotypes (carbapenemase-positive or negative) [27–
30]. P. aeruginosa belonging to ST313 and ST274 have been
already described as intestinal colonisers in healthy humans
[8], although ST274 has been also previously described in
carbapenem-susceptible P. aeruginosa isolates [3, 8], asso-
ciated with cystic fibrosis patients, and is considered as an
epidemic clone circulating in Spain [29, 31, 32]. P. aeruginosa
strains ascribed to ST27, ST252, ST253 (clonal complex PA14),
ST395, and ST560 have been previously observed in clinical
animal and environmental samples [14, 27, 31, 33, 34].
Considering P. aeruginosa pathogenicity, this species pos-
sesses at least twowell-defined and interrelated quorum sens-
ing (QS) systems, las and rhl. These signalling mechanisms
are used to regulate gene expression through the produc-
tion and secretion of autoinducers called N-acylhomoserine
lactones, produced by lasI and rhlI genes, which activate
LuxR family regulators, LasR and RhlR, respectively [35].
These systems control the production of different virulence
factors, including elastases (LasB andLasA), alkaline protease
(AprA), hydrogen cyanide, exotoxin A, pyocyanin, lectins,
rhamnolipids (RhlA and RhlB), and superoxide dismutase
[36–38]. In our study, the genes implicated in QS system,
las and rhl, were amplified in most of the P. aeruginosa
isolates. However, rhlI and rhlR genes were absent in one
strain, rhlR gene were in other three strains, and lasI and
lasR genes were not amplified in two more strains. Moreover,
the insertion sequence IS1394was found truncating lasR gene
in one P. aeruginosa strain. Several reports have mentioned
the frequency of lasRmutations among clinical and environ-
mental isolates [39, 40] and have demonstrated that a lasR
mutation does not lead to loss of virulence factors thanks to
the regulation mediated by rhlR gene [41].
One important determinant of virulence is the T3SS,
which is present in several Gram-negative bacilli, including
Salmonella, Shigella, and Yersinia spp. In P. aeruginosa, the
T3SS is a major virulence weapon that contributes to cyto-
toxicity and acute infections [42]. P. aeruginosa is able to pro-
duce and secrete virulence factors directly. This secretion
system injects potent ExoS and ExoT (two ADP-ribosylatin
enzymes), ExoU (acute cytolytic factor), and ExoY (an adeni-
late cyclase) exotoxins into the cytoplasm of the host cells by a
cell contact-mediatedmechanism [43–48]. ExoU is one of the
most important virulence determinants of P. aeruginosa and
is associated with an increased risk of early clinical mortality
[49–51]. In our study, two strains showed the infrequent
exoU/exoS-positive genotype, which has been rarely reported
[52, 53]. Additionally, other 24 of our strains amplified
the exoU gene (33% of total) that belonged to important
clinical STs, such as ST253 or ST560, among others. This is
a high percentage of exoU presence, considering that these
strains were recovered from healthy children. Defined clonal
lineages are expected to be linked to specific T3SS genotypes.
Indeed, in a Spanish multicenter study, the vast majority of
the extensively drug resistant (XDR) isolates belonged to the
high-risk clones ST175 and ST111, which showed in all cases
an exoU-negative/exoS-positive genotype, and to the ST235
clone that showed an exoU-positive/exoS-negative genotype
[54].
5. Conclusion
This work assesses for the first time occurrence of P.
aeruginosa in faecal samples of children from two different
geographical Spanish regions, providing fundamental infor-
mation about antimicrobial resistance, virulence, and the
genetic lineages of the recovered isolates. These faecal P.
aeruginosa isolates were characterised by their high clonal
diversity, great variety of genetic lineages, low antimicrobial
resistance percentages, and variability of virulence patterns.
Intestinal colonisation by P. aeruginosa, mainly belonging
to international clones (such as ST244, ST253, or ST274),
is an important factor for the development of systemic
infections and the environmental dissemination. Periodic
active surveillance is useful to identify these community
human reservoirs and control the evolution of antibiotic
resistance carriage and virulence activity over time.
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